OptimizeRx (OPRX) Set to Release Earnings on Wednesday

OptimizeRx (NASDAQ:OPRX – Get Free Report) will likely be issuing its Q3 2026 results after the market closes on Wednesday, November 11th. Analysts expect the company to post earnings of $0.18 per share and revenue of $21.19 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, November 11, 2026 at 4:30 PM ET.

OptimizeRx (NASDAQ:OPRX – Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported $0.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.05. OptimizeRx had a net margin of 4.66% and a return on equity of 9.44%. The company had revenue of $20.50 million for the quarter, compared to analysts’ expectations of $20.20 million. On average, analysts expect OptimizeRx to post $0.49 EPS for the current fiscal year and $0.66 EPS for the next fiscal year.

OptimizeRx Stock Up 8.1%

OPRX stock opened at $9.47 on Tuesday. OptimizeRx has a 12 month low of $4.54 and a 12 month high of $16.84. The firm has a market cap of $178.41 million, a PE ratio of 41.18 and a beta of 1.20. The firm has a 50 day simple moving average of $8.38 and a 200 day simple moving average of $7.27. The company has a debt-to-equity ratio of 0.14, a current ratio of 5.58 and a quick ratio of 5.58.

Analyst Upgrades and Downgrades

Several research firms have issued reports on OPRX. Citigroup reaffirmed a “market outperform” rating on shares of OptimizeRx in a report on Tuesday, October 27th. UBS Group set a $11.00 price objective on OptimizeRx in a research note on Friday, August 14th. Weiss Ratings upgraded OptimizeRx from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, August 25th. Wall Street Zen lowered OptimizeRx from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 20th. Finally, Citizens Jmp upped their target price on OptimizeRx from $9.00 to $11.00 and gave the company a “market outperform” rating in a report on Friday, August 14th. Six analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $11.57.

View Our Latest Analysis on OPRX

About OptimizeRx

(Get Free Report)

OptimizeRx Corporation (NASDAQ: OPRX) is a digital health and life sciences technology company that helps pharmaceutical and biotechnology companies connect with healthcare professionals and patients. Its platform supports prescription-related communications, treatment access, affordability, adherence and patient engagement throughout the medication journey.

The company provides solutions that can be integrated into electronic health records and other healthcare workflows. Its offerings include point-of-care messaging for healthcare professionals, patient support and savings programs, medication access tools, and data and analytics services designed to help life sciences companies communicate with relevant audiences and understand engagement.

OptimizeRx was founded in 2006 and has primarily served the U.S.

Further Reading

Earnings History for OptimizeRx (NASDAQ:OPRX)

Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.